Cervical intraepithelial neoplasia

Overview: What Is Cervical Intraepithelial Neoplasia?

Cervical intraepithelial neoplasia (CIN) — sometimes called cervical dysplasia or cervical precancer — is a condition in which abnormal cells develop on the surface of the cervix, the lower, narrow part of the uterus that connects to the vagina.

The word breaks down simply:

• Cervical – relating to the cervix
• Intraepithelial – within the surface layer of cells (the epithelium)
• Neoplasia – abnormal, disordered cell growth

A crucial point to understand from the start: CIN is not cancer. It is a precancerous condition, meaning the abnormal cells have the potential — but not the certainty — to develop into cervical cancer over time. For most patients, CIN either resolves on its own or is easily treated before cancer ever develops. This is precisely why cervical screening programmes have been so successful: they catch these changes years before they could become dangerous.

CIN is classified into three grades (CIN 1, CIN 2 and CIN 3) depending on how abnormal the cells look and how deeply they extend into the surface layer of the cervix.

Key Facts at a Glance

What Is the Cervix and Where Does CIN Develop?

The cervix is the lower opening of the uterus, roughly 2–3 cm long, shaped like a small cylinder or donut. It is lined by two types of cells:

• Squamous cells – flat, skin-like cells covering the outer portion (visible during a speculum examination)
• Columnar (glandular) cells – mucus-producing cells lining the inner canal

The two cell types meet at an area called the transformation zone (TZ). This junction shifts position over a woman’s lifetime, and because the cells here are constantly changing (a process called squamous metaplasia), this zone is biologically “busy” — and therefore vulnerable. Around 90% of cervical precancers and cancers arise in the transformation zone. This is why screening samples and colposcopy examinations focus on this specific area.

Causes: The Role of Human Papillomavirus (HPV)

The overwhelming cause of CIN is persistent infection with high-risk types of human papillomavirus (HPV).

Understanding HPV

HPV is an extremely common group of more than 200 related viruses, spread through intimate skin-to-skin and sexual contact. Key facts:

• Most sexually active people (an estimated 80%) will acquire HPV at some point in their lives.
• In about 90% of cases, the immune system clears the virus naturally within 1–2 years, causing no harm.
• Only when a high-risk HPV type persists for years can it trigger the cell changes that lead to CIN.
• HPV types 16 and 18 are responsible for roughly 70% of cervical cancers; types 31, 33, 45, 52 and 58 account for most of the remainder.
• Low-risk types (notably HPV 6 and 11) cause genital warts, but not CIN or cancer.

How HPV causes abnormal cells

High-risk HPV infects the basal (deepest) cells of the cervical epithelium. The virus produces proteins called E6 and E7, which switch off the cell’s natural “brakes” — tumour suppressor proteins known as p53 and pRb. With these safety mechanisms disabled, cells begin to divide in a disorganised way, accumulating abnormalities. If the immune system does not eliminate the infection, these changes can deepen over years, progressing through CIN grades and, eventually, potentially to invasive cancer.

It is important to remember: having HPV does not mean you will develop CIN, and having CIN does not mean you will develop cancer. HPV is common; persistent disease is not.

Risk Factors

While HPV infection is the necessary cause, certain factors make persistent infection and abnormal cell changes more likely:

• Early onset of sexual activity (the transformation zone is more vulnerable during adolescence)
• Multiple sexual partners, or a partner with multiple partners
• Weakened immune system — including HIV infection, immunosuppressive medicines (e.g., after organ transplantation), or long-term corticosteroid use
• Smoking — tobacco by-products concentrate in cervical mucus and damage local immune defences; smokers have roughly double the risk of persistent disease
• Long-term use of combined oral contraceptives (5+ years) — associated with a modestly increased risk
• Multiple full-term pregnancies (particularly three or more)
• Co-infection with other sexually transmitted infections, such as chlamydia or herpes simplex virus
• Not attending cervical screening — the single most modifiable risk factor for undetected disease
• Not being vaccinated against HPV

Note:** CIN itself is not contagious. HPV is transmitted between partners; the cell changes it causes are not.

Classification and Grades of CIN

CIN is graded according to what proportion of the epithelial thickness is occupied by abnormal cells, as seen under the microscope. This grading directly guides treatment decisions.

You may also encounter alternative terminology:

• SIL (Squamous Intraepithelial Lesion) – used in Pap test reports; LSIL (low-grade) broadly corresponds to CIN 1, and HSIL (high-grade) to CIN 2/3.
• CGIN / AIS – glandular cell abnormalities of the cervix (cervical glandular intraepithelial neoplasia / adenocarcinoma in situ), a related but distinct glandular-cell precancer.

It typically takes 10–20 years for an untreated high-grade lesion to become invasive cancer, which is why there is usually ample time for detection and treatment.

How Does It Look

One of the most important things for patients to understand is that CIN usually cannot be seen with the naked eye — either by the patient or even by a doctor performing a routine examination.

To the naked eye

• In most cases, the cervix looks completely normal even when CIN 2 or CIN 3 is present.
• CIN does not typically form lumps, bumps, warts or ulcers. (Genital warts are caused by different, low-risk HPV types and look entirely different.)
• Occasionally, a hardened white patch (leukoplakia) may be visible, but this is non-specific.

Because of this, you cannot check yourself for CIN, and feeling “perfectly healthy” does not rule it out. Only testing can detect it.

Under colposcopy (magnified visual examination)

During a colposcopy, the doctor examines the cervix with a specialised magnifying instrument after applying gentle solutions that make abnormal areas visible:

The combination of these features allows the colposcopist to estimate the severity of the lesion and choose where to take biopsies.

Under the microscope (histology)

Definitive diagnosis rests on examining a biopsied tissue sample. The pathologist sees characteristic changes:

• Disorganised maturation — cells fail to flatten and mature normally as they move toward the surface
• Nuclear abnormalities — enlarged, dark-staining (hyperchromatic), irregularly shaped nuclei
• Increased nuclear-to-cytoplasmic ratio — the nucleus occupies an unusually large share of the cell
• Increased and abnormally located cell division (mitoses) — including division in the upper epithelial layers, where it should not occur
• Loss of polarity — cells lose their orderly alignment
• Koilocytes — cells with a distinctive “halo” around the nucleus, a direct footprint of HPV infection (typical of CIN 1)

The depth of these changes up the epithelium determines the grade: lower third = CIN 1; two-thirds = CIN 2; full thickness = CIN 3 (carcinoma in situ).

Symptoms

In the great majority of cases, CIN causes no symptoms at all. Most people feel entirely well and discover the condition only through a routine cervical screening test. This is why screening is essential — you cannot rely on how you feel.

When symptoms do occur (and they may come from the CIN itself or from co-existing conditions such as infection), they can include:

• Bleeding after sexual intercourse (post-coital bleeding)
• Bleeding between periods (intermenstrual bleeding)
• Bleeding after menopause
• Unusual vaginal discharge — watery, blood-tinged or persistent discharge
• Heavier or longer periods than usual
• Pelvic pain or pain during intercourse — uncommon with CIN itself, and more suggestive of infection or, rarely, more advanced disease

### ⚠️ Important – These symptoms are non-specific — far more often they are caused by benign conditions (cervical ectropion, infections, polyps) than by CIN or cancer. Nevertheless, any abnormal bleeding warrants medical assessment. – Do not wait for symptoms to have a screening test.** The entire purpose of screening is to find cell changes before they cause symptoms. – Worsening symptoms such as persistent pelvic pain, foul-smelling discharge or unexplained weight loss should be assessed urgently.

Diagnosis and Screening

Diagnosis of CIN follows a stepwise pathway:

1. Cervical screening tests

• Pap test (cervical cytology): Cells are gently brushed from the cervix and examined for abnormalities. Results may be reported as normal, LSIL, HSIL or other categories.
• HPV DNA test: Detects high-risk HPV types in the sample. Many countries now use this as the primary screening test, as it identifies risk earlier than cytology alone.

Screening intervals vary by country (commonly every 3 years for cytology, every 5 years for HPV testing), typically beginning between ages 21 and 25 and continuing to ages 60–65. Follow your national programme’s guidance.

2. Colposcopy

If screening is abnormal, a colposcopy is performed — a painless-to-mildly-uncomfortable outpatient examination (5–20 minutes) using a magnifying instrument and the solutions described above.

3. Biopsy

One or more small tissue samples are taken from abnormal-looking areas during colposcopy. Only biopsy can confirm CIN and its grade. Sometimes the inner canal is sampled too (endocervical curettage). Mild cramping and light spotting afterwards are normal.

Treatment

Treatment depends on the grade of CIN, age, future pregnancy plans, and HPV status. Modern management balances eliminating disease against preserving fertility.

Treatment by grade

Treatment methods

Excisional (removal) procedures — the mainstay of treatment:

• LLETZ / LEEP (Large Loop Excision of the Transformation Zone / Loop Electrosurgical Excision Procedure): A thin wire loop carrying electrical current removes the abnormal area under local anaesthetic. It takes minutes, allows the tissue to be examined afterwards, and is the most common treatment worldwide.
• Cold knife cone biopsy (conisation): A cone-shaped wedge of cervix is removed surgically; used for larger lesions, glandular disease (CGIN/AIS) or suspected early invasion.
• Laser conisation: Similar principles using a laser beam.

Ablative (destructive) procedures — used less often, when the entire lesion is visible and invasive disease has been excluded:

• Cryotherapy (freezing the abnormal cells)
• Laser ablation or cold coagulation (thermocoagulation)

Hysterectomy is reserved for exceptional situations — persistent, recurrent high-grade disease despite treatment, or when other gynaecological conditions coexist. It is not a routine treatment for CIN.

Possible side effects of treatment

Most people recover quickly, but it is important to know about:

• Light bleeding or watery discharge for 2–4 weeks (infection signs — fever, foul discharge, heavy bleeding — need review)
• Advice to avoid intercourse, tampons and swimming for several weeks to allow healing
• Cervical stenosis (scarring/narrowing of the cervical canal) — uncommon
• Pregnancy considerations: excisional treatment is associated with a small increase in the risk of preterm birth in future pregnancies (related to the amount of tissue removed). This risk is modest, adjustable by technique, and should be discussed with your doctor if you plan pregnancy — the risk of leaving CIN 2/3 untreated far outweighs it.

Follow-Up After Treatment

Treatment removes the abnormal cells, but follow-up confirms the HPV infection is gone:

• A “test of cure” is usually performed about 6 months after treatment — primarily an HPV test (with or without cytology).
• If HPV is negative, the risk of recurrence is very low, and you return to routine screening intervals.
• If HPV persists, closer monitoring (often annual) continues; persistent positive tests around 3 years after treatment usually trigger repeat colposcopy.
• Follow-up is essential — recurrence risk exists (roughly 5–10%), and it is highest in the first few years, especially if the virus persists.

Prognosis

The outlook for CIN is excellent:

• CIN 1: approximately 60% regress spontaneously within a year; fewer than 1% progress toward cancer.
• CIN 2–3, treated: success rates exceed 90–95% with a single procedure.
• CIN 3 left untreated: evidence from long-term studies indicates around 30% may progress to invasive cancer within 30 years — the compelling reason detection and treatment matter.

Regular screening and timely treatment mean that cervical cancer is one of the most preventable of all cancers.

Prevention

1. HPV vaccination

The most powerful primary prevention tool. Current vaccines (e.g., the 9-valent vaccine) protect against HPV types 16 and 18 plus five additional high-risk types — covering around 90% of cervical cancer-causing infections — as well as the types causing genital warts.

• Most effective when given before exposure to the virus, ideally at ages 9–14.
• Catch-up vaccination is recommended into young adulthood (up to age 26 in many programmes); adults aged 27–45 can discuss individual benefit with a doctor.
• Vaccination does not treat existing HPV infection or CIN, and vaccinated individuals still need screening.

2. Regular cervical screening

Attend all screening appointments according to your national programme — even if vaccinated, even if you feel perfectly well.

3. Lifestyle measures

• Stop smoking — smoking markedly impairs clearance of HPV from the cervix.
• Use condoms — they reduce (though do not eliminate) HPV transmission.
• Manage immune health — for people living with HIV, effective antiretroviral therapy and more frequent screening are vital.
• Treat other STIs promptly.

Living with a CIN Diagnosis

Receiving a letter saying your screening was “abnormal” can be frightening, and anxiety is common and understandable. Helpful perspectives to hold on to:

• Abnormal screening results are very common; cancer is not. The vast majority of abnormal results reflect minor changes or treatable precancer.
• CIN says nothing about your character, cleanliness or worth — HPV is nearly universal among sexually active people.
• CIN and its treatments do not affect fertility in the overwhelming majority of cases, and most people go on to have normal pregnancies.
• You can still have a normal sex life; HPV may be shared with partners, but this does not require partners to be tested (routine HPV testing is not available for men) and is not a reason for blame.
• Ask questions, bring someone with you to appointments, and seek support from reputable sources if anxiety persists.

Questions you may wish to ask your doctor

• What grade of CIN do I have, and what does it mean for me?
• Do I need treatment now, or can we monitor it safely?
• What are the risks and benefits of each option for someone of my age and family plans?
• When is my next test, and what happens at it?

When to See a Doctor

Seek medical advice if you experience:

• Bleeding after sex, between periods, or after menopause
• Unusual or persistent vaginal discharge
• Ongoing pelvic pain or pain during sex
• Any symptoms that worry you, even if mild

And, most importantly: attend screening whenever invited, and don’t delay follow-up appointments after an abnormal result.

Summary

Cervical intraepithelial neoplasia is a precancerous change of the cervical cells caused by persistent high-risk HPV infection. It produces no symptoms in most cases, cannot be seen with the naked eye, and is detected through screening, colposcopy and biopsy. Graded from CIN 1 to CIN 3, it is managed by careful monitoring or minor outpatient surgery with outstanding success rates. Thanks to HPV vaccination and regular screening, the progression from CIN to cervical cancer is now largely preventable — making this a condition where awareness genuinely saves lives.

References

1. Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J. and Bray, F. (2020) ‘Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis’, The Lancet Global Health, 8(2), pp. e191–e203.
2. Castle, P.E. (2017) ‘The evolving definition of carcinogenic human papillomavirus’, Infectious Agents and Cancer, 12, p. 37.
3. Doorbar, J., Quint, W., Banks, L., Bravo, I.G., Stoler, M., Broker, T.R. and Stanley, M.A. (2012) ‘The biology and life-cycle of human papillomaviruses’, Vaccine, 30(Suppl 5), pp. F55–F70.
4. Kyrgiou, M., Athanasiou, A., Paraskevaidi, M., Mitra, A., Kalliala, I., Martin-Hirsch, P., Arbyn, M., Bennett, P. and Paraskevaidis, E. (2017) ‘Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis’, BMJ, 354, i3633.
5. Lei, J., Ploner, A., Elfström, K.M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner, J. and Sparén, P. (2020) ‘HPV vaccination and the risk of invasive cervical cancer’, New England Journal of Medicine, 383(14), pp. 1340–1348.
6. McCredie, M.R.E., Sharples, K.J., Paul, C., Baranyai, J., Medley, G., Jones, R.W. and Skegg, D.C.G. (2008) ‘Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study’, The Lancet Oncology, 9(5), pp. 425–434.
7. National Health Service (NHS) (2023) Cervical screening. Available at: https://www.nhs.uk/conditions/cervical-screening/ (Accessed: January 2025).
8. Perkins, R.B., Guido, R.S., Castle, P.E., Chelmow, D., Einstein, M.H., Garcia, F., Huh, W.K., Kim, J.J., Moscicki, A.-B., Nayar, R., Saraiya, M., Sawaya, G.F., Wentzensen, N. and Schiffman, M. (2020) ‘2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors’, Journal of Lower Genital Tract Disease, 24(2), pp. 102–131.
9. Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J., Garcia, F.A.R., Moriarty, A.T., Waxman, A.G., Wilbur, D.C., Wentzensen, N., Downs, L.S., Spitzer, M., Moscicki, A.-B., Franco, E.L., Stoler, M.H., Schiffman, M., Castle, P.E. and Myers, E.R. (2012) ‘American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer’, CA: A Cancer Journal for Clinicians, 62(3), pp. 147–172.
10. Schiffman, M. and Wentzensen, N. (2013) ‘Human papillomavirus infection and the multistage carcinogenesis of cervical cancer’, Cancer Epidemiology, Biomarkers & Prevention, 22(4), pp. 553–560.
11. Walboomers, J.M.M., Jacobs, M.V., Manos, M.M., Bosch, F.X., Kummer, J.A., Shah, K.V., Snijders, P.J.F., Peto, J., Meijer, C.J.L.M. and Muñoz, N. (1999) ‘Human papillomavirus is a necessary cause of invasive cervical cancer worldwide’, The Journal of Pathology, 189(1), pp. 12–19.
12. World Health Organization (2021) WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. 2nd edn. Geneva: World Health Organization.

Disclaimer: This article is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the guidance of your physician or another qualified health provider with any questions you may have regarding a medical condition.